je.st
news
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda (pembrolizumab) as First-line Treatment for Advanced Melanoma
2015-10-13 13:30:03| Merck.com - Product News
Dateline City: WILMINGTON, Del. and KENILWORTH, N.J. Pivotal study to evaluate Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with advanced or metastatic melanoma WILMINGTON, Del. and KENILWORTH, N.J. -- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incytes investigational selective IDO1 inhibitor, with Keytruda (pembrolizumab), Mercks anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Language: English read more
Tags: for
advanced
include
study
Category:Biotechnology and Pharmaceuticals